Blockchain Registration Transaction Record

Tonix Pharma Gets FDA Nod for Phase 2 Lyme Vaccine Study

Tonix Pharmaceuticals receives FDA support for Phase 2 trial of TNX-4800, a long-acting antibody to prevent Lyme disease. Learn about the study design and pipeline.

This news matters because it signals progress in the fight against Lyme disease, a growing public health concern in the U.S. With the FDA's support, Tonix is moving closer to a potential preventative treatment that could offer six months of protection per dose, addressing a significant unmet medical need. If successful, TNX-4800 could become a seasonal immunopreventative, reducing the burden of Lyme disease for millions at risk. For investors, this development also highlights Tonix's pipeline strength beyond its marketed products, potentially impacting the company's valuation and future revenue streams.